fda semaglutide shortage lawsuit 📢 has determined the of injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Patients and prescribers may still see intermittent and limited localized supply disruptions as the Novo Nordisk expands legal action

Murphy, W

PMID: 23818527

The trial included 60 adult participants (mean age approximately 49) who had clinical follow-up with labs every 2 months for up to 2 years, with some withdrawing early due to spontaneous remission, indication for definitive therapy (e.g., thyroidectomy or radioiodine), or an intolerance to the treatment

A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation

Lose Weight with GLP-1 GLP-1 offers a promising path to substantial weight loss, with many users seeing significant results within a few months